quinazolines has been researched along with thioctic acid in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Decker, M; Heilmann, J; Kraus, B | 1 |
| Adachi, E; Matsugo, S; Matsumoto, K; Michikoshi, H; Nakamura, T; Sakai, K; Suzuki, Y | 1 |
2 other study(ies) available for quinazolines and thioctic acid
| Article | Year |
|---|---|
Design, synthesis and pharmacological evaluation of hybrid molecules out of quinazolinimines and lipoic acid lead to highly potent and selective butyrylcholinesterase inhibitors with antioxidant properties.
Topics: Acetylcholinesterase; Animals; Antioxidants; Butyrylcholinesterase; Cell Line; Cell Survival; Cholinesterase Inhibitors; Drug Design; Imines; Mice; Molecular Structure; Quinazolines; Reactive Oxygen Species; Structure-Activity Relationship; Substrate Specificity; Thioctic Acid | 2008 |
α-Lipoic acid-induced inhibition of proliferation and met phosphorylation in human non-small cell lung cancer cells.
Topics: Antioxidants; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; G1 Phase Cell Cycle Checkpoints; Gefitinib; Humans; Lung Neoplasms; Mutation; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Quinazolines; Reactive Oxygen Species; Receptor, ErbB-2; Thioctic Acid | 2013 |